 |
18 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- parsatuzumab (RG7414) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4976;
Currently, MCL patients are treated with aggressive chemo-immunotherapy regimens followed mostly by consolidation with autologous stem cell transplantation and maintenance rituximab...To examine the therapeutic potential of targeting EGFL7 in MCL cells, we treated patient-derived xenograft (PDX) cells (n=3) with an anti-EGFL7 blocking antibody (Parsatuzumab) in vitro...Further, Anti-EGFL7 treatment decreased phospho-AKT protein levels in PDX cells and MCL cell lines compared to IgG control, suggesting blocking EGFL7 abrogates EGFR mediated downstream signals. In conclusion, this is the first report describing a role for EGFL7 in MCL growth and/or survival by modulating the EGFR-AKT signaling pathway and targeting EGFL7 using an anti-EGFL7 blocking antibody as a novel treatment to improve the outcome for MCL patients.
- | Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche, paclitaxel / Generic Mfg.
Biomarker, Clinical, P2 data, Journal, Combination therapy: Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. (Pubmed Central) - Sep 22, 2019
In conclusion, this is the first report describing a role for EGFL7 in MCL growth and/or survival by modulating the EGFR-AKT signaling pathway and targeting EGFL7 using an anti-EGFL7 blocking antibody as a novel treatment to improve the outcome for MCL patients. There was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line NS-NSCLC.
- |||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 26, 2016
P2, N=127, Completed, Sponsor: Genentech, Inc.
There was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line NS-NSCLC. Terminated --> Completed
- | Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial termination, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=128, Terminated, Sponsor: Genentech, Inc.
Terminated --> Completed Completed --> Terminated
- Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 2, 2015
P2, N=128, Completed, Sponsor: Genentech, Inc.
Completed --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Feb 2014
- Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Enrollment closed, Combination therapy, Metastases: Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) (clinicaltrials.gov) - Dec 6, 2014
P2, N=104, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Feb 2014 Completed --> Active, not recruiting
- || Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial primary completion date, Combination therapy, Metastases: Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) (clinicaltrials.gov) - May 11, 2014
P2, N=104, Completed, Sponsor: Genentech
Completed --> Active, not recruiting Trial primary completion date: Apr 2014 --> Feb 2013
- || Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion date, Combination therapy, Metastases: Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) (clinicaltrials.gov) - May 11, 2014
P2, N=104, Completed, Sponsor: Genentech
Trial primary completion date: Apr 2014 --> Feb 2013 Trial completion date: Apr 2014 --> Aug 2013
- |||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion, Combination therapy, Metastases: Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) (clinicaltrials.gov) - May 11, 2014
P2, N=104, Completed, Sponsor: Genentech
Trial completion date: Apr 2014 --> Aug 2013 Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Enrollment closed, Combination therapy, Metastases: Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) (clinicaltrials.gov) - Jan 5, 2014
P2, N=104, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion, Combination therapy, Metastases: A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 7, 2013
P1, N=64, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Enrollment closed, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 5, 2012
P2, N=128, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | parsatuzumab (RG7414) / Roche
Trial completion, Metastases: A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 7, 2012
P1, N=30, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed